OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

Published

April 28, 2022

OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B

The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets…

MORERelated News
Introducing Fierce Biotech’s 2024 Fierce 15 – OMass Therapeutics
What makes OMass fierce: You can’t fault OMass for its ambition. The company may still be in preclinical development, but it...
Dame Carol Robinson to receive Lifetime Achievement Award for groundbreaking protein analysis work
The European Patent Office (EPO) has announced that Dame Carol Robinson, Professor of Chemistry at the University of Oxford, will receive...
5 Pharmaceutical Companies in the UK to Know
OMass uses high-resolution mass spectrometry to study protein assemblies and discover new medicines. Its spectrometry platform, called OdyssION, enables better visualization...